Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy

R B Stricker1, B Barlogie, D D Kiprov

  • 1Department of Medicine, California Pacific Medical Center, San Francisco.

The Journal of Rheumatology
|February 1, 1994
PubMed
Summary

Interferon-alpha therapy can trigger autoimmune disorders. A multiple myeloma patient developed a fatal bleeding disorder due to antibodies against factor VIII after this treatment, highlighting a need for further research.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.

Leukemia·2018
Same author

Drug response prediction in high-risk multiple myeloma.

Gene·2017
Same author

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.

Nature communications·2017
Same author

Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma.

Leukemia·2017
Same author

NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma.

Leukemia·2017
Same author

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.

Blood cancer journal·2017

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • Interferon-alpha (IFN-alpha) is used therapeutically but linked to autoimmune complications.
  • Autologous bone marrow transplantation is a treatment for multiple myeloma.

Observation:

  • A patient with multiple myeloma received chronic IFN-alpha treatment post-transplantation.
  • This patient developed an inhibitor antibody against factor VIII coagulant protein (FVIIIC).

Findings:

  • The FVIIIC inhibitor antibody led to a severe, fatal hemorrhagic diathesis.
  • This case illustrates a specific autoimmune complication associated with IFN-alpha therapy.

Implications:

  • The link between IFN-alpha treatment and autoimmune disorders requires broader recognition.

Related Experiment Videos

  • Further investigation into IFN-alpha-induced autoimmunity is warranted, particularly in hematologic malignancies.